John Calicchio, DO
Family Medicine · Hackettstown, NJNPI 1760458699
Payments from drug & device makers
Across 257 payments — averaging $13.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$666
- AbbVie$554
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$305
- Otsuka America Pharmaceutical, Inc.$261
- Lilly USA, LLC$226
- Pfizer$217
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,595100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $666 |
| AbbVie(2 entities) | 43 | $554 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $305 |
| Otsuka America Pharmaceutical, Inc. | 17 | $261 |
| Lilly USA, LLC | 17 | $226 |
| Pfizer | 15 | $217 |
| Amarin Pharma, Inc. | 12 | $171 |
| Merck | 12 | $157 |
| Amgen(2 entities) | 8 | $111 |
| GSK | 6 | $89 |
| Astellas Pharma US Inc | 4 | $82 |
| Lundbeck LLC | 6 | $81 |
| AstraZeneca | 6 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $66 |
| Kowa Pharmaceuticals America, Inc. | 5 | $65 |
| Boehringer Ingelheim | 4 | $59 |
| Teva Pharmaceuticals USA, Inc. | 4 | $55 |
| Sanofi Pasteur Inc. | 3 | $47 |
| Adlon Therapeutics L.p. | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $34 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Kaleo, Inc. | 2 | $24 |
| Dynavax Technologies Corporation | 2 | $19 |
| Bausch Health US, LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
How this compares
$3,595 in reported general payments places this provider in the 80th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 55 | $59,780 |
| OzempicSemaglutide | 39 | $43,210 |
| EliquisApixaban | 42 | $41,889 |
| TradjentaLinagliptin | 20 | $27,776 |
| JardianceEmpagliflozin | 23 | $27,259 |
| XareltoRivaroxaban | 20 | $19,640 |
| MyrbetriqMirabegron | 19 | $14,808 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $12,150 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $7,299 |
| Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine | 19 | $7,115 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $5,525 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,551 |
| Atorvastatin Calcium | 329 | $3,242 |
| Varenicline Tartrate | 12 | $3,184 |
| Levothyroxine Sodium | 227 | $2,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat | $59 | $67,18555 claims |
| MerckJanuvia | $157 | $59,78055 claims |
| Novo NordiskOzempic | $666 | $43,21039 claims |
| PfizerEliquis | $217 | $41,88942 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $14,80819 claims |
| GSKIncruse Ellipta | $89 | $4,55113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Hackettstown
- Bijal DaveHackettstown$25K
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.